Cargando…

Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas

Bexarotene, a drug approved for treatment of cutaneous T-cell lymphoma (CTCL), is classified as a rexinoid by its ability to act as a retinoid X receptor (RXR) agonist with high specificity. Rexinoids are capable of inducing RXR homodimerization leading to the induction of apoptosis and inhibition o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warda, Ankedo, Staniszewski, Lech J. P., Sabir, Zhela, Livingston, Sarah, Sausedo, Michael, Reshi, Sabeeha, Ron, Eyal, Applegate, Michael T., Haddad, Dena, Khamisi, Madleen, Marshall, Pamela A., Wagner, Carl E., Jurutka, Peter W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647404/ https://www.ncbi.nlm.nih.gov/pubmed/37947652 http://dx.doi.org/10.3390/cells12212575

Ejemplares similares

Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB)
por: Jurutka, Peter W., et al.
Publicado: (2021)

An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene
por: Jurutka, Peter W., et al.
Publicado: (2022)

Vitamin D Receptor Mediates a Myriad of Biological Actions Dependent on Its 1,25‐Dihydroxyvitamin D Ligand: Distinct Regulatory Themes Revealed by Induction of Klotho and Fibroblast Growth Factor‐23
por: Haussler, Mark R, et al.
Publicado: (2020)

Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma
por: Morita, Akimichi, et al.
Publicado: (2022)

Pomegranate derivative urolithin A enhances vitamin D receptor signaling to amplify serotonin-related gene induction by 1,25-dihydroxyvitamin D
por: Livingston, Sarah, et al.
Publicado: (2020)

Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin
por: Nosova, Yulia N., et al.
Publicado: (2017)

Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
por: Cervigón-González, Iván, et al.
Publicado: (2011)

Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma
por: Illidge, T, et al.
Publicado: (2013)

Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T‐cell lymphoma
por: Morita, Akimichi, et al.
Publicado: (2020)

Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy
por: Sato, Yota, et al.
Publicado: (2018)

A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats
por: Ren, Shuyue, et al.
Publicado: (2020)

Preclinical PET Neuroimaging of [(11)C]Bexarotene
por: Rotstein, Benjamin H., et al.
Publicado: (2016)

Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma
por: Tanita, Kayo, et al.
Publicado: (2019)

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses
por: ROUANET, Jacques, et al.
Publicado: (2022)

CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas
por: Yamamoto, Jun, et al.
Publicado: (2023)

Photodegradation of Bexarotene and Its Implication for Cytotoxicity
por: Kryczyk-Poprawa, Agata, et al.
Publicado: (2021)

Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene
por: Zhang, X., et al.
Publicado: (2012)

Successful Treatment of Primary Cutaneous Peripheral T-Cell Lymphoma Presenting Acquired Ichthyosis with Oral Bexarotene Monotherapy
por: Tanita, Kayo, et al.
Publicado: (2017)

The utility of bexarotene in mycosis fungoides and Sézary syndrome
por: Panchal, Manisha R, et al.
Publicado: (2015)

Bexarotene-Induced Hypertriglyceridemia: A Case Report
por: Maminakis, Chris, et al.
Publicado: (2018)

Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada
por: Elsea, David, et al.
Publicado: (2023)

Identification of Bexarotene as a PPARγ Antagonist with HDX
por: Marciano, David P., et al.
Publicado: (2015)

Time to next treatment and safety assessment in cutaneous‐T‐cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Bexarotene Gel: A New Topical Therapy for Alopecia Areata
por: Rajiv, Mahajan, et al.
Publicado: (2010)

The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence
por: Tousi, Babak
Publicado: (2015)

Bexarotene: A Rare Cause of Misleading Thyroid Function Tests
por: Pattan, Vishwanath, et al.
Publicado: (2020)

Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement
por: Xiao, Fu, et al.
Publicado: (2022)

FRI511 Bexarotene: A Deceptive Cause Of Iatrogenic Hypothyroidism
por: Ghaith, Sarah, et al.
Publicado: (2023)

Bexarotene – a novel modulator of AURKA and the primary cilium in VHL-deficient cells
por: Chowdhury, Pratim, et al.
Publicado: (2018)

Long‐term efficacy and safety of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: The results of a phase 2 study (B‐1201)
por: Hamada, Toshihisa, et al.
Publicado: (2019)

Identification of putative transcriptomic biomarkers in irritable bowel syndrome (IBS): Differential gene expression and regulation of TPH1 and SERT by vitamin D
por: Grozić, Aleksandra, et al.
Publicado: (2022)

Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency
por: Schlotawa, Lars, et al.
Publicado: (2023)

Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico
por: Rosenthal, Joseph, et al.
Publicado: (2016)

Effectiveness of combined bexarotene and excimer laser treatment for folliculotropic mycosis fungoides
por: Furukawa, Fumina, et al.
Publicado: (2021)

High-Dose Thyroid Hormone Replacement in Bexarotene-Induced Central Hypothyroidism
por: Mathews, Tony, et al.
Publicado: (2021)

Remyelination varies between and within lesions in multiple sclerosis following bexarotene
por: Brown, J. William L., et al.
Publicado: (2022)

Bexarotene improves motor function after spinal cord injury in mice
por: Wang, Xingyu, et al.
Publicado: (2023)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

When the dust settles: what did we learn from the bexarotene discussion?
por: Tesseur, Ina, et al.
Publicado: (2013)

Correction: Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico
por: Rosenthal, Joseph, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9nib4i6ousr8ohvefpk8hk7lc9